Chief Medical Officer, Chief Scientific Officer & Senior Vice President of Oncology, Flatiron Health
Before joining Flatiron, Amy was Professor of Medicine at Duke University School of Medicine, and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. For more than a decade, she has pioneered the development of technology platforms to spur novel advancements in cancer care, including the development of systems by which big data can support personalized medicine and scientific discovery. Joining Flatiron was the obvious next step.
Amy went to the University of Pennsylvania as an undergraduate, and then medical school at Duke, where she also did her Internal Medicine residency, a year as Chief Resident, and her hematology/oncology fellowship. She has her PhD from Flinders University in Australia, focused on evidence-based medicine. As an oncologist and palliative care physician, she sincerely believes in putting the patient in the center of the health care story and ensuring that the solutions we build have patient best interests at heart. She is also a mother of two and an avid traveler.
With over 375 publications, Amy is an internationally recognized expert in health services research, comparative effectiveness research, patient reported outcomes, clinical informatics and patient-centered care. She maintains her role at Duke 20 percent, and is an appointee to the Institute of Medicine’s National Cancer Policy Forum, Immediate Past President of the American Academy of Hospice & Palliative Medicine, Secretary of the Board of Directors for the Personalized Medicine Coalition, and leader within several federally-funded research networks. She serves on the Advisory Committee of the Turning the Tide Against Cancer policy initiative. She also serves on the Board of Directors for athenahealth.
Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.
Previously Dr. Abrahams was executive director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.
Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.
The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.
Founder, Chair & Lung Cancer Survivor, Bonnie J. Addario Lung Cancer Foundation (ALCF)
Bonnie has been an activist, advocate, educator and change agent empowering patients and giving them a strong voice in the fight against lung cancer since receiving a stage 3B diagnosis more than a decade ago. Although thrust into a role that she had never envisioned for herself, she embraced it and now considers it to be her second career and a personal calling. Recognizing the critical need for education, empowerment, advocacy and research to help patients and families, especially those without resources and support, Bonnie and her family founded the Bonnie J. Addario Lung Cancer Foundation (ALCF) in 2006, and then went on to found the Addario Lung Cancer Medical Institute (ALCMI) with her husband, Tony Addario, in 2008. Bonnie’s business acumen and skills honed in her first career as President of Olympian Oil Company and Commercial Fueling Network (CFN), as Past President of the CA Independent Oil Marketers Association (CIOMA) and as a community activist serving on diverse boards have all contributed to her work at ALCF in developing business strategies and being the Foundation’s patient voice at national/international conferences, on panels and boards, and to industry leaders, clinicians and policy makers. Bonnie’s personal interests include collecting wine, travel, sports (Go SF Giants!) and spending time with family and friends at Lake Tahoe.
Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb Company
Dr. Averbuch is Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb. In this role, Dr. Averbuch is responsible for the execution of external clinical collaborations for the company’s immuno-oncology pipeline. Dr. Averbuch also leads the Pharmacodiagnostics Center of Excellence, whose mission is to drive biomarker strategy, optimize biomarker knowledge and tools across all of R&D and execute on the integrated co-development and co-commercialization of diagnostic tests as companions to Bristol-Myers Squibb medicines.
Dr. Averbuch joined Bristol-Myers Squibb in 2006. Prior to his current role, he co-led the Oncology early strategy team, and he was the executive sponsor for Oncology Transition Teams for the execution of Phase 2 Oncology programs. He has made significant Global Clinical Research contributions to business development, and he has participated in multiple successful licensing and acquisition deals.
Dr. Averbuch previously held positions at Merck Research Laboratories, AstraZeneca and Mount Sinai School of Medicine. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland.
Dr. Averbuch has authored over 60 peer reviewed publications and book chapters, and he is a co-author on one patent. He is currently on the Personalized Medicine Coalition Board of Directors, the Steering Committee of the National Biomarker Development Alliance, the Advisory Board for the University of Kansas Institute for Advancing Medical Innovation, and he is a member of the American Society of Clinical Oncology and the American Association for Cancer Research having served on multiple committees for both organizations. Dr. Averbuch is the 2014 recipient of the University of Illinois College of Medicine Distinguished Alumnus Award.
Chairman, Biological Dynamics, Inc.
Board certified internist and clinical geneticist, Dr. Paul R. Billings is the Chairman of Biological Dynamics, Inc., an innovative cancer testing company in San Diego, CA. Prior to this position, Dr. Billings was the Chief Medical Officer of Life Technologies Inc. (Lifetech) and then the Chief Medical Officer (consulting) of the Genetic Sciences Division of ThermoFisher Scientific (TFS), both unique positions aimed at improving patient care by expanding the use of medically relevant genomic technologies in clinical settings.
Dr. Billings has extensive expertise and health care experience in the areas of genomics and molecular medicine. Dr. Billings has served on the Scientific Advisory Board of the FDA and the Genomic Medicine Advisory Committee at the U.S. Department of Veterans Affairs. He is currently a member of the IOM Genomics Roundtable at National Academy of Sciences, and serves on other for-profit and not-for-profit Boards, including the Council for Responsible Genetics, the country’s oldest independent biotechnology “watchdog” organization.
Dr. Billings is also the author of nearly 200 publications and books on experimental and clinical medicine. His work on genetic discrimination was instrumental in the creation and passage of the federal Genetic Information Non-Discrimination Act of 2008.
Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University.
Chief Medical Office & Executive Vice President, Science & Regulatory Affairs, PhRMA
Dr. William W. Chin is the Executive Vice President for Science and Regulatory Advocacy and Chief Medical Officer at PhRMA where he leads PhRMA’s continuing efforts in science and regulatory advocacy in the drug discovery and development ecosystem. He was the Executive Dean for Research, Bertarelli Professor of Translational Medical Science and Professor of Medicine at Harvard Medical School (HMS). In this role, Dr. Chin spearheaded efforts to design and implement the vision for research at HMS, with special emphasis on interdisciplinary and translational research that crosses departmental and institutional boundaries.
Chin is a Harvard-trained endocrinologist and longstanding faculty member. His impressive career is exemplified in part by his extensive bibliography of nearly 300 papers, chapters and books, most of which were generated during his 25 years on the Harvard Medical School faculty. During his tenure as a faculty member in the Department of Medicine at Brigham and Women’s Hospital, he became Chief of the Genetics Division and a Howard Hughes Medical Institute investigator, advancing to Professor of Medicine, and Obstetrics, Gynecology and Reproductive Biology at HMS. As a pioneering molecular endocrinologist at HMS, Dr. Chin embraced the early use of emerging DNA technology to make important discoveries regarding the structure, function and regulation of hormone genes. His investigations often demonstrated a translational research theme, connecting basic laboratory discoveries to their physiologic relevance in animal models and humans. He has been honored with numerous awards for research, mentorship and leadership. Prior to HMS, Dr. Chin was at Eli Lilly and Company, where he had worked for the last decade, most recently as senior vice president for Discovery Research and Clinical Investigation. He received his A.B. (Chemistry, summa cum laude) from Columbia University and his M.D. from Harvard Medical School.
President & CEO, Change Healthcare
de Crescenzo was appointed President and Chief Executive Officer of Change
Healthcare in September 2013. Change Healthcare is a leading provider of
software and analytics, network solutions, and technology-enabled services whose
Intelligent Healthcare Network® is one of the largest financial and
administrative networks in the United States health care system generating
revenues of over $1.4 billion annually.
to Change Healthcare, Mr. de Crescenzo was Senior Vice President and General
Manager of Oracle’s Global Health Sciences business. Previously, he spent a
decade at IBM Corporation including his last role as senior executive for
Global Healthcare Business Consulting Services. Earlier in his career, he held
leadership positions in a major hospital system, a large physician practice and
at a major health insurer. Mr. de Crescenzo began his career in investment
banking, working with U.S. and European clients in the areas of corporate
finance and mergers and acquisitions.
de Crescenzo earned a B.A. in Political Science from Yale University and an
M.B.A. from Northeastern University. He also currently serves on the Board of Directors of the Nashville Health Care
Council and on the Executive Committee of
Healthcare Leadership Council.
President & CEO, Global Liver Institute
Donna R. Cryer, J.D., has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as president and chief executive officer of the Global Liver Institute, the innovation and collaboration platform for the liver community. Ms. Cryer most recently served as chair, president and chief executive officer of the American Liver Foundation, the largest and oldest national nonprofit organization serving liver disease patients and their families. She was the first patient to lead the organization in its 36-year history.
For eight years, Ms. Cryer has led CryerHealth, a health care consulting firm providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations, and emerging technology firms on patient engagement in health information technology, drug discovery, and clinical decision making.
Her e-health experience includes participating in the launch of the Office of National Coordinator for HIT (ONC) consumer engagement campaign and serving on the ONC technical expert panel on patient-generated health data, participating as a member of the White House e-health equity taskforce and the judging panel on the White House design challenge on innovating the electronic patient medical record. Her blog, DCpatient – An Impatient Patient’s Perspective from Washington, DC, and twitter feed @DCpatient are listed as top resources for insights into emerging e-patients and patient advocates.
Ms. Cryer is a patient representative to the U.S. Food and Drug Administration, a merit reviewer for the Patient Centered Outcomes Research Institute (PCORI), and a member of the Stakeholder Advisory Group to the NIH Learning Health System Research Collaboratory. Additionally, Ms. Cryer serves on the Gastroenterology Board of the American Board of Internal Medicine, the American Society of Clinical Oncology Guidelines Committee; Hepatitis B Infection Screening in Patients Receiving Chemotherapy for Treatment of Malignant Diseases, the Board of the Personalized Medicine Coalition, is a member of the Patient and Consumer Advisory Council for the Center for Medical Technology Policy, and is an adviser to HarborPath, a patient assistance program for those living with HIV/AIDS and HCV.
Ms. Cryer received an undergraduate degree from Harvard/Radcliffe Colleges and received a Juris Doctorate from the Georgetown University Law Center.
She resides in Washington, DC, with her husband, Dennis R. Cryer, MD, FAHA.
Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Dr. William “Bill” S. Dalton is Founder and CEO of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to his role as the President, CEO & Center Director of Moffitt Cancer Center, Dr. Dalton was the Dean of the University of Arizona College of Medicine.
Dr. Dalton is interested in the development of personalized cancer care and patient-centered outcomes research through Moffitt’s nationally renowned Total Cancer CareTM approach to developing evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care includes one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated to the development of personalized medicine. He is also recognized as a founder of ORIEN, an alliance of cancer centers who have agreed to use the Total Cancer Care protocol to generate and share data for collaborative research and learning. For his leadership in this area, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and personalized medicine.
Vice President, Oncology Medical Sciences, Astellas Pharma Global Development
Dr. Eck is Vice President of Oncology Medical Sciences at Astellas Pharma Global Development (Headquartered in Northbrook, IL). He is directly responsible for the oversight of oncology drug development plans. Much of this work is focused on special cancer populations for which unique biology enables the development of personalized cancer therapies. Dr. Eck previously served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company (2007-2011) where he was responsible for the clinical pharmacology components of drug development including both early phase clinical studies and late stage drug development studies. His group also developed the biomarkers and companion diagnostics needed for effective decision-making and for tailoring therapeutics to the right patient population. Prior to Joining Lilly, Dr. Eck served in a variety of drug development leadership roles at Pfizer, Inc (2002-2007).
Dr. Eck is a board certified Hematologist/Oncologist with broad drug development experience in Oncology and Neuroscience. He is a Fellow of the American Association for the Advancement of Science (Pharmaceutical Sciences). He serves on the Scientific Advisory Board of the ACGT Foundation (which supports academic cancer research), and was a member of the Executive Committee of the Fairbanks Institute (an institution dedicated to developing data banks to enable personalized medicine) from 2007-2012. He also serves on the Advisory Board of the College of Pharmacy at the Keck Graduate School (Claremont, CA).
Senior Vice President & Chief Medical Officer, Medicines Development Unit & Lilly Research Laboratories, Eli Lilly & Company
Dr. Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice- President and Co-Leader of the Medicines Development Unit managing Medical Affairs, Medical Strategy and Development, Global Health Outcomes and Real World Evidence, Global Regulatory, Global Patient Safety, Clinical Development in China and Japan, and Early Phase Medicine for Eli Lilly and Company. During his 17 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director – Duloxetine SUI Team; and European Clinical Research Physician for EVISTA.
Prior to joining Lilly, Dr. Garnett had acquired 7 years of experience, holding a variety of positions in the pharmaceutical industry in Europe with Organon Laboratories.
He qualified in Medicine at St. George’s Hospital in London. He practiced Obstetrics and Gynecology for eight years prior to joining the pharmaceutical industry and conducted clinical research into menopause, pre-menstrual tension and post menopausal osteoporosis.
Dr. Garnett is a Fellow of the Royal College of Obstetricians and Gynecologists in the United
Kingdom. He is also an active board member for the following: Centre for Innovation in
Regulatory Science; Indiana Health Industry Forum; and
Eiteljorg Museum of American Indians and Western Art.
President & Chief Executive Officer, NanoString Technologies
R. Bradley Gray has served as a member of NanoString's board of directors and as President & Chief Executive Officer since June 2010. Prior to joining the company, Mr. Gray held various positions at Genzyme, a biotechnology company acquired by Sanofi in 2011. He served as Vice President of Product & Business Development for Genzyme Genetics, the diagnostic services division of Genzyme, from June 2008 to May 2010, leading the development of molecular diagnostics and partnering activities. From September 2006 to June 2008, he served as Vice President of Business & Strategic Development for Genzyme Genetics, leading growth efforts through partnerships and licensing. Mr. Gray joined Genzyme in October 2004 as Director of Corporate Development, supporting business development and leading Genzyme Ventures, the corporate venture capital fund of Genzyme. Prior to joining Genzyme, Mr. Gray was a management consultant in the health care practice of McKinsey & Company, a global management consulting firm, from September 2000 to October 2004, where he worked with senior health care executives in the United States and Europe on a broad range of issues including pharmaceutical and diagnostic product strategy, post-merger integration, organization design and operational turnarounds. Mr. Gray received a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.
Chief Executive Officer & President, CareDx
Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Dr. Maag was President of Novartis Diagnostics based in Emeryville, California. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Dr. Maag also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis' headquarters in Switzerland, he helped launch the Infectious Diseases franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Maag worked for 6 years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Supporting various health care and high tech companies in their growth efforts, he holds board and advisory positions at Phoenix, MolecularMD and Cobaltix. Dr. Maag studied pharmaceutical sciences in Heidelberg and London, and received his Ph.D. from the University of Berlin, Germany.
Founder & Publisher, Genome magazine
Susan brings 29 years of journalistic experience to her role as Publisher for Genome magazine — the first consumer magazine exclusively devoted to personalized medicine and genomics. With over 300,000 copies distributed across the US each quarter, Genome covers the personalized medicine stories of today and the breakthroughs of tomorrow, so that patients have the information they need to get the targeted treatments they deserve. Prior to its launch, she spent 10 years as the publisher of CURE — a magazine for cancer patients, survivors and caregivers. During her tenure at CURE, she also served as Vice President of Patient Engagement for McKesson Specialty Health. In 2016, Susan was honored by Folio as one of the “Top Women in Media” for her entrepreneurial efforts in magazine publishing and media. She has over 20 years of experience delivering first-class sales and management strategies to leading and start-up media and health care organizations, and is especially skilled at creating collaborative partnerships that result in highly respected educational offerings for patients and health care providers.
Medical Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Dr. Howard McLeod is the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He is also a Senior Member of the Division of Population Sciences. Most recently, he was the Fred Eshelman Distinguished Professor and Founding Director of the UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill. Dr. McLeod held appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Comprehensive Cancer Center.
Dr. McLeod is also chair of the
NHGRI eMERGE network external scientific panel and a recent member of the FDA
committee on Clinical Pharmacology and the NIH NHGRI Advisory Council. Since 2002, Dr McLeod has been vice chair for
Pharmacogenomics for the NCI clinical trials cooperative group CALGB/ALLIANCE,
overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is also a 1000 talent scholar of
China and a professor at Central South University in Changsha, China. He directs the Pharmacogenetics for Every
Nation Initiative, which aims to help developing countries use genetic
information to improve National Drug Formulary decisions.
Dr. McLeod has also been an active entrepreneur, serving
on the Board of Directors, Scientific Advisory Board, and as a domain expert
consultant to for-profit companies. He
has founded both for-profit and non-profit companies in the USA and China. Howard has published more than 475 peer reviewed
papers on pharmacogenomics, applied therapeutics or clinical pharmacology and
continues to work to integrate genetics principles into clinical practice to
advance individualized medicine.
Senior Vice President, Government Affairs, Endo Pharmaceuticals
Brian Munroe is the founder and the immediate Past-President of the Personalized Medicine Coalition (PMC). He currently serves as the Chairman of the PMC Public Policy Committee and on the Executive Committee of the PMC Board of Directors.
Brian is a twenty year veteran of health care public policy, advocacy, and communications. His areas of expertise are in FDA legislation and regulations, Medicare and Medicaid reimbursement, federal and state tax policy, and the development of government policies to advance personalized medicine.
Brian has created successful, stand alone Government Affairs Departments from scratch at: SmithKline Beecham, Millennium Pharmaceuticals, and Endo Pharmaceuticals. He is currently the Vice-President in charge of Washington office, the Public Policy group, State Government Relations and, the Political Action Committee at Endo. He also serves on Endo’s Executive Operations Committee.
Brian’s breadth in health care policy stretches across pharma/biotech, home health care, diagnostics, medical devices, clinical laboratories, and health care payors. His geographical responsibilities have included the fifty states, the Federal government and Congress, and for a short time the European Union and member countries.
Brian began his career in Washington, D.C. working for United States Senator Alan Cranston (D-CA).
Brian currently lives in the Washington, D.C. area with his wife Vicky and their four children.
Chairman, Foundation Medicine
Dr. Pellini currently serves as the Chairman of Foundation Medicine’s Board of Directors. Dr. Pellini joined Foundation Medicine as President and Chief Executive Officer in May 2011, bringing a breadth of experience in life sciences and the clinical diagnostics and laboratory industries to the company. Dr. Pellini came to Foundation Medicine from Clarient, a GE Healthcare Company, where he held the position of President and Chief Operating Officer. Dr. Pellini joined GE Healthcare through the integration of Clarient, Inc., where he worked with the company’s leadership team to drive operational excellence and reimbursement strategies in parallel with the development and commercialization of multiple diagnostic tests. Dr. Pellini’s leadership was instrumental in building Clarient to the highly successful acquisition by GE Healthcare in October 2010.
Prior to his tenure with Clarient, Dr. Pellini served as Vice President, Life Sciences at Safeguard Scientifics, Inc. where he leveraged his business and medical expertise to explore new market opportunities and to support Safeguard’s partner companies. Prior to Safeguard, he was Executive Vice President and Chief Operating Officer at Lakewood Pathology Associates, a national molecular pathology services company, which was acquired by Water Street Healthcare Partners in 2006. Previously, Dr. Pellini was an Entrepreneur-in-Residence at BioAdvance, where he was responsible for identifying early-stage life science opportunities. He also served as President and Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004.
Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College of Thomas Jefferson University. He is a board member of the Personalized Medicine Coalition and serves on the President’s Leadership Council of Jefferson Medical College.
Chairman of the Board, Chief Executive Officer & President, Genomic Health
Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the over-treatment and optimal treatment of early-stage cancer, one of the greatest issues in health care today.
Kim has served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation. Kim currently serves on the boards of the California Life Sciences Association (CLSA), the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), and ZS Pharma. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Adviser to the Healthcare Businesswomen’s Association (HBA).
Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area from 2006-2012 by the San Francisco Business Times. She was also named Woman of the Year in 2008 by the Women Health Care Executives.
Kim holds a Bachelor of Arts degree in Business from Michigan State University.
Vice President & Head of Diagnostics, Enterprise Scientific Technology Operations, Worldwide R&D
Hakan leads Pfizer’s Companion
Diagnostics efforts across the Worldwide R&D organization and is also
responsible for Pfizer’s internal Biobank group. His formal education includes BS
(1983) and MS (1984) degrees from Ankara University in Turkey, PhD (1990) in
Quantitative Genetics from the University of Minnesota as a Rotary Foundation
Scholar, and postdoctoral studies in genetics at the University of
in the biotech industry in human genetics and statistical genetics fields
across multiple disease areas before moving to Parke-Davis Pharmaceuticals in
1998 to direct human genetics, statistical genetics and pharmacogenetics
programs. Following the merger of
Warner-Lambert/Parke-Davis with Pfizer, he has held positions of increasing responsibility
in Clinical Pharmacogenomics, Molecular Profiling, and Translational
Oncology. Hakan interacted closely with
Pfizer’s Executive Leadership Team and the Board of Directors to define and
implement Pfizer’s current companion diagnostics strategy. One of his most significant professional
accomplishments was to lead the companion diagnostics program for Xalkori®
(Crizotinib), Pfizer’s flagship program in companion diagnostics. Hakan served on the clinical development and
drug/diagnostics submission teams and led the companion diagnostics program to
a successful delivery, resulting in simultaneous FDA approvals of both the drug
and the companion diagnostic test in 2011.
Hakan was then promoted to his current role to provide companion
diagnostics leadership across Pfizer’s pharmaceutical pipeline. He led the internal efforts that resulted in
companion diagnostics partnerships with Dako/Agilent and Siemens Healthcare
Diagnostics, among others. Hakan’s
contributions to precision medicine and companion diagnostics have been widely
recognized through both internal and external awards, frequent speaking
engagements, and press coverage. He is
the author of over 30 referred scientific articles as well as many other
papers, abstracts and book chapters.
Hakan is keenly interested in technologies for identification of patient sub-groups for targeted treatments and development of companion diagnostics to advance Precision Medicine for the improvement of individualized health care. He is an active member of civic clubs, and enjoys cycling, soccer, and stand-up paddle-boarding.
Senior Vice President, Chief Medical Officer, Harvard Pilgrim Health Care
Dr. Michael Sherman serves as Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care. He works with physicians and health care organizations to achieve sustainable improvements in cost and quality. He has focused the organization on introducing innovative, outcomes-based reimbursement models and developing outcomes-based payment agreements. Dr. Sherman is the chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and also serves on the Advisory Board of the Institute for Clinical and Economic Review (ICER), the Board of Directors and as co-President of the Harvard Business School Healthcare Alumni Association, the Board of Advisors for the Harvard Business School Healthcare Initiative, and Board of Overseers for Boston’s Museum of Science.
Prior to joining Harvard Pilgrim, Dr. Sherman served as Corporate Medical Director, Physician Strategies, for Humana and held several leadership positions with UnitedHealth Group, Thomson Medstat (now IBM Truven), HealthAllies and Immusol.
Dr. Sherman holds a B.A. in anthropology and natural sciences and an M.S. in biomedical anthropology from the University of Pennsylvania. He received his M.D. from Yale and an M.B.A. from the Harvard Business School.
Chief Medical Officer, Unum Therapeutics
Michael Vasconcelles, M.D. is responsible for defining the strategic vision and leading the execution of Unum’s clinical program. He is an industry veteran with extensive experience in managing multiple clinical programs.
Dr. Vasconcelles previously served as Senior Vice President and Global Head for Oncology at Takeda Pharmaceuticals. While there, he led the development of the oncology portfolio from candidate selection through life cycle management, including a portfolio of marketed oncology products and throughout all stages of preclinical and clinical development.
Prior to 2012, Dr. Vasconcelles served as Global Therapeutic Area Head, Transplant and Oncology, at Genzyme. He was responsible for the clinical development and product support of Genzyme's hematologic transplant and oncology portfolio. As a member of the Transplant and Oncology Management team, and Chair of the Transplant and Oncology R&D Council, Dr. Vasconcelles also provided strategic support and oversight to oncology research, business development and commercial strategy for the business. In 2011, following the acquisition of Genzyme by Sanofi, he led the realignment of Genzyme Oncology R&D with Sanofi Global Oncology and was named the Head, Personalized Medicine and Companion Diagnostics.?
Before he joined Genzyme, Dr. Vasconcelles was a full time associate physician at Brigham and Women's Hospital and Dana-Farber Cancer Institute. He remains an associate physician at both institutions. He has been on the faculty of the Harvard Medical School since 1996, where he is currently a clinical instructor of medicine.?
Dr. Vasconcelles recieved both his B.A. and his M.D. from Northwestern University.
Chief Medical Officer and Senior Vice President, Quest Diagnostics
Jay G. Wohlgemuth, M.D., is Chief Medical Officer and Senior Vice President, Research & Development and Medical for Quest Diagnostics. Based at Quest Diagnostics Nichols Institute, in San Juan Capistrano, California, Dr. Wohlgemuth is responsible for Research & Development (R&D), Medical Affairs and Medical/Lab Quality. In addition, he is responsible for improving outcomes for employees who use Quest's health benefits.
Dr. Wohlgemuth has many years of experience in medical diagnostics and research and development. He rejoined Quest in 2016 from HealthTap, a health information start-up, where he served as Senior Vice President and Chief Healthcare Officer. Prior to that, he was Senior Vice President, R&D, Medical and Chief Scientific Officer with Quest. Dr. Wohlgemuth originally joined Quest in 2009 from Genentech, where he was Director, Clinical Diagnostics, ITGR (Immunology, Tissue Growth and Repair) and Global Development Team Leader for Ocrulizumab. He also served as Vice President, Research and Development for VIA Pharmaceuticals and as Chief Medical Officer for the molecular diagnostics company XDx, a company he co-founded. In addition, Dr. Wohlgemuth served as Vice President, Research & Development for XDx. For his work at XDx he was awarded Technology Pioneer 2005 at the World Economic Forum in Davos. He serves on the Board of Directors for the Diagnostic Labs of Oklahoma and The Anne and Henry Zarrow Charitable Foundation.
Dr. Wohlgemuth earned his bachelor’s degree in biology from Harvard College and his medical degree from Stanford University School of Medicine, where he also served a fellowship in cardiovascular medicine.